UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 131

Sortiert nach

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

The Lancet (British edition), 2012-11, Vol.380 (9856), p.1829-1839

2012

Volltextzugriff (PDF)

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

The Lancet (British edition), 2012-11, Vol.380 (9856), p.1819-1828

2012

Volltextzugriff (PDF)

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

Journal of clinical immunology, 2010-01, Vol.30 (1), p.99-105

2010

Volltextzugriff (PDF)

Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years

Multiple sclerosis and related disorders, 2020-08, Vol.43, p.102146, Article 102146

2020

Volltextzugriff (PDF)

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis

European Journal of Immunology, 2005-11, Vol.35 (11), p.3332-3342

2005

Volltextzugriff (PDF)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286420982134-1756286420982134

2021

Volltextzugriff (PDF)

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Neurology, 2017-09, Vol.89 (11), p.1117

2017

Volltextzugriff (PDF)

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Neurology, 2017-09, Vol.89 (11), p.1107

2017

Volltextzugriff (PDF)

Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations

Neurology, 2013-12, Vol.81 (24), p.2073

2013

Volltextzugriff (PDF)

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

Journal of neurology, 2020-11, Vol.267 (11), p.3343-3353

2020

Volltextzugriff (PDF)

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

Multiple sclerosis, 2019-10, Vol.25 (12), p.1605-1617

2019

Volltextzugriff (PDF)

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

Journal of neurology, neurosurgery and psychiatry, 2012-03, Vol.83 (3), p.298-304

2012

Volltextzugriff (PDF)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Neurology, 2016-11, Vol.87 (19), p.1985

2016

Volltextzugriff (PDF)

Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation

PloS one, 2012-02, Vol.7 (2), p.e30708-e30708

2012

Volltextzugriff (PDF)

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Lancet neurology, 2011-04, Vol.10 (4), p.338-348

2011

Volltextzugriff (PDF)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

Neurology, 2016-10, Vol.87 (14), p.1464

2016

Volltextzugriff (PDF)

Association of the human leucocyte antigen region with susceptibility to Parkinson's disease

Journal of neurology, neurosurgery and psychiatry, 2010-08, Vol.81 (8), p.890-891

2010

Volltextzugriff (PDF)

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

Journal of neurology, neurosurgery and psychiatry, 2015-02, Vol.86 (2), p.208-215

2015

Volltextzugriff (PDF)

Immune competence after alemtuzumab treatment of multiple sclerosis

Neurology, 2013-09, Vol.81 (10), p.872

2013

Volltextzugriff (PDF)

Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72

Journal of neurology, neurosurgery and psychiatry, 2013-01, Vol.84 (1), p.79-87

2013

Volltextzugriff (PDF)

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

The New England journal of medicine, 2008-10, Vol.359 (17), p.1786-1801

2008

Volltextzugriff (PDF)

Osteopontin gene and clinical severity of multiple sclerosis

Journal of neurology, 2003-08, Vol.250 (8), p.943-947

2003

Volltextzugriff (PDF)

Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey

Brain (London, England : 1878), 2000-06, Vol.123 ( Pt 6) (6), p.1102-1111

2000

Volltextzugriff (PDF)

Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansion of MO/PF72

Journal of neurology, neurosurgery and psychiatry, 2013, Vol.84 (1), p.79-87

2013

Volltextzugriff (PDF)

Genetic variation in nitric oxide synthase 2A ( ) and risk for multiple sclerosis

Genes and immunity, 2008-09, Vol.9 (6), p.493-500

2008

Volltextzugriff (PDF)

1 – 25 von 131

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(117)

Publikationsform

Artikel
(131)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Nature Genetics
(13)
Human Molecular Genetics
(10)
Plos One
(9)
Journal Of Neuroimmunology
(8)
Brain
(6)
Journal Of Neurology, Neurosurgery And Psychiatry
(6)
Neurology
(6)
Nature
(5)
American Journal Of Human Genetics
(4)
Annals Of Neurology
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS

Association of the human leucocyte antigen region with susceptibility to Parkinson's disease

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

Immune competence after alemtuzumab treatment of multiple sclerosis

Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

Osteopontin gene and clinical severity of multiple sclerosis

Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey

Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansion of MO/PF72

Genetic variation in nitric oxide synthase 2A ( ) and risk for multiple sclerosis

Suchergebnisse filtern